Biotechnology Press Releases
Breaking News
-
EIN News Launches Celgene Daily Report
Washington, January 25, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company since 1995, has announced the launch of Celgene Daily Report. For more news see: - Celgene Foundations News - http://celgene.einnews.com/news/celgene-foundations -...
-
Amarantus BioSciences Licenses Disease Diagnostic Biomarker Test from Power3 Medical Products
Amarantus BioSciences Licenses Parkinson's Disease Diagnostic Biomarker Test from Power3 Medical Products /EINPresswire.com/ SUNNYVALE, CA and THE WOODLANDS, TX - January 23, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology...
-
Amarantus BioSciences Interview at the 2012 Biotech Showcase
/EINPresswire.com/ SUNNYVALE, CA - January 20, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, was interviewed at the 2012 Biotech Showcase in...
-
TCT Receives Patent on Therapeutic Monoclonal Antibody Targeting Pancreatic Cancer
/EINPresswire.com/ SANTA ROSA, CA, (1/18/12) --Targeted Cancer Therapeutics LLC (TCT) announced that its anti-CEACAM6 product received the U.S. Designation of Patent Number 8,038,996. The patent claims allow for a method of treating various...
-
Geron Corporation Daily Report Launched by EIN News
Washington, January 16, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company published by the IPD Group, has announced the launch of Geron Corporation Daily Report. For more details see: - Geron Biotechnology News - http://geron.einnews.com/news/geron-biotechnology -...
Press Releases
Biotechnology
-
Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid Arthritis
Benitec Biopharma (ASX: BLT) and Medistem (PINKSHEETS: MEDS) announced today the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma's patented gene silencing technology applied to stem cell-derived immune...
-
OphthaliX Announces the Appointment of Prof. Roger Kornberg as a Director
OphthaliX Announces the Appointment of Prof. Roger Kornberg as a Director PR Newswire CARSON CITY, Nev. , Feb. 6, 2012 /PRNewswire/ -- OphthaliX Inc. (OTCBB: OPLI) is pleased to announce the appointment of Professor Roger D. Kornberg...
-
BioMed Realty Trust to Acquire Cambridge Place For $119 Million
BioMed Realty Trust to Acquire Cambridge Place For $119 Million Acquisition will expand total Boston/Cambridge, Massachusetts portfolio to approximately 3.2 million square feet PR Newswire SAN...
-
GC-Global Capital Corp. Announces the Election of Mr. Cesare Fazari to Its Board of Directors
GC-Global Capital Corp. (TSX VENTURE:GDE.A) ("Global Capital" or "the Company") is pleased to announce that Mr. Cesare Fazari has joined as a member of the board of directors of Global Capital as well as a member of the Company's governance...
-
'Camera in a Pill' Endoscopy Sees Increasing Acceptance and Sales
Driven by innovative devices such as capsule endoscopes, the entire gastrointestinal device market grew to $14.6 billion in 2011, according to healthcare market research publisher Kalorama Information. Capsule endoscopy has been one of the fastest...
-
Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results Luminex achieves 30 percent annual revenue growth PR Newswire AUSTIN, Texas , Feb. 6, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced...
-
Ardea Biosciences Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exercise of an over-allotment option previously...
-
Aberdeen Australia Equity Fund, Inc. Announces Performance Data and Portfolio Composition
Aberdeen Australia Equity Fund, Inc. Announces Performance Data and Portfolio Composition PR Newswire PHILADELPHIA , Feb. 6, 2012 /PRNewswire/ -- Aberdeen Australia Equity Fund, Inc. (the "Fund") (NYSE AMEX: IAF), a closed-end equity...
-
Statewide Network of Angel Investor Groups Announced in Alabama
Statewide Network of Angel Investor Groups Announced in Alabama PR Newswire HUNTSVILLE, Ala. , Feb. 6, 2012 /PRNewswire/ -- The Angel Investor Management (AIM) Group announced today the formation of the Central...
-
Proteonomix, Inc. (PROT) Brings in Additional Leadership in Order to Expand Management
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has brought in new executive management as part of a new staffing effort...
-
Cleveland BioLabs to Present at 14th Annual BIO CEO and Investor Conference
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 14th Annual BIO CEO and Investor Conference, February 13-14, in New York, NY. Neil Lyons, Chief Financial Officer for Cleveland BioLabs,...
-
MMRGlobal to Lead International Revenue Push at HIMSS 2012
MMRGlobal, Inc. (OTCBB: MMRF) ("MMR"), a leading provider of Personal Health Records ("PHR"), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals , today announced its global...
-
Novelos Therapeutics to Present at the 14th Annual Bio CEO & Investor Conference on February 13
Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the 14 th...
-
Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients Positive Phase 2 Study Results Presented in 'Best Abstracts' Oral Session at the 2012 BMT Tandem Meetings ...
-
Q4 2011 Marks Completion of Record Year for Resolvit, LLC
Overall Revenue Up Nearly 30 Percent Over 2010; Employment Up 14 Percent Over Same Period Resolvit, LLC, an information technology and business consulting solutions provider, today announced that it has set new company revenue and employment...
Follow us
What people say
Our Partners
© 2005-2012